India Glycols Share Price

Please find attached

• BSE India
• 18 hours 15 minutes ago

<h3><span style="font-size:16px;"><strong>Commodity Chemicals company India Glycols announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Total Income for Q1FY27 was Rs 2,988.82 crore, an increase of 26.61% QoQ from Rs 2,360.63 crore in Q4FY26 and a growth of 19.34% YoY compared to Rs 2,504.52 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Revenue from operations stood at Rs 2,988.44 crore in Q1FY27, representing a growth of 26.63% QoQ from Rs 2,360.01 crore in Q4FY26 and 19.39% YoY from Rs 2,503.12 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">EBITDA for Q1FY27 was Rs 169.94 crore, compared to Rs 167.12 crore in Q4FY26 and Rs 151.04 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Profit before tax for the quarter Q1FY27 was Rs 122.88 crore, up 9.27% QoQ from Rs 112.46 crore in Q4FY26 and a significant increase of 35.73% YoY from Rs 90.53 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Net Profit after tax for Q1FY27 reached Rs 96.83 crore, growing 11.45% QoQ from Rs 86.88 crore in Q4FY26 and 32.19% YoY from Rs 73.25 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Total Comprehensive Income for Q1FY27 stood at Rs 96.68 crore, as against Rs 86.08 crore in Q4FY26 and Rs 72.82 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Earnings Per Share (EPS) for Q1FY27 was Rs 14.45, compared to Rs 13.64 in Q4FY26 and Rs 11.83 in Q1FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Total Income for Q1FY27 was Rs 2,987.30 crore, growing by 24.44% QoQ from Rs 2,400.60 crore in Q4FY26 and 19.28% YoY from Rs 2,504.43 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Revenue from operations stood at Rs 2,986.92 crore in Q1FY27, an increase of 26.49% QoQ from Rs 2,361.40 crore in Q4FY26 and 19.33% YoY from Rs 2,503.03 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">EBITDA for Q1FY27 was Rs 170.30 crore, compared to Rs 203.42 crore in Q4FY26 and Rs 149.26 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Profit before tax for Q1FY27 was Rs 102.64 crore, a decline of 24.41% QoQ from Rs 135.78 crore in Q4FY26 but a growth of 46.36% YoY compared to Rs 70.13 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427="">Net Profit after tax for the quarter Q1FY27 was Rs 76.59 crore, down 30.55% QoQ from Rs 110.28 crore in Q4FY26 (impacted by lower other income) and up 44.92% YoY from Rs 52.85 crore in Q1FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Business Highlights:</strong></p> <ul _ngcontent-ng-c1940132427=""> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Segment-wise Revenue Performance:</strong> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Bio-based Specialities and Performance Chemicals:</strong> Recorded revenue of Rs 363.25 crore in Q1FY27, a growth of 21.09% YoY from Rs 299.99 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Potable Spirits:</strong> Revenue stood at Rs 2,218.67 crore in Q1FY27, up 22.91% YoY from Rs 1,805.06 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Ennature Biopharma:</strong> Segment revenue was Rs 83.30 crore in Q1FY27, representing a growth of 64.95% YoY from Rs 50.50 crore in Q1FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Bio-Fuel:</strong> Revenue declined to Rs 323.22 crore in Q1FY27, compared to Rs 347.57 crore in Q1FY26.</li> </ul> </li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Scheme of Arrangement:</strong> The Board of Directors had approved a Composite Scheme of Arrangement for the demerger of the Bio Pharma undertaking into "Ennature Bio Pharma Limited" and the Spirits & Biofuel undertaking into "IGL Spirits Limited." The NCLT sanctioned the Scheme on July 17, 2026, with an appointed date of April 1, 2026. Certified copies of the order are awaited.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Performance of Demerged Entities (Q1FY27):</strong> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">India Glycols Limited:</strong> Revenue from operations was Rs 354.64 crore with an EBITDA of Rs 40.22 crore.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">IGL Spirits Limited:</strong> Revenue from operations reached Rs 2,541.89 crore with an EBITDA of Rs 120.10 crore.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Ennature Bio Pharma Limited:</strong> Revenue from operations was Rs 90.39 crore with an EBITDA of Rs 9.98 crore.</li> </ul> </li> </ul> <p><a class="lb" href="/get-document/post/pdf/5783932/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 day 19 hours ago

Please find attached.

• BSE India
• 1 day 20 hours ago